JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis With KBI Biopharma, Inc.
JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to acquire Selexis SA, a pioneering life sciences company and global leader in mammalian (suspension-adapted CHO-K1) cell-line generation technologies. Once completed, this transaction will mark the second major biotechnology addition to the JSR group of companies following JSR Corporation’s acquisition of KBI Biopharma in 2015. Selexis will be integrated within KBI Biopharma’s operations to create the most robust and fastest “Gene to GMP” service offering in the biopharmaceutical industry.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170614005189/en/
“Selexis has the best-in-class cell-line development technology and offers the ability to solve some of the most difficult expression challenges in biologics development,” said Eric R. Johnson, President of JSR’s Life Sciences Division. “JSR holds quality as the highest of its values and we see that same focus in Selexis. The Selexis technologies seamlessly integrate into the biologics development continuum, spanning discovery to commercialization. This allows us – in conjunction with KBI Biopharma – to move one step closer in our vision to become the biologics contract development and manufacturing organization (CDMO) of the 21st century.”
With biopharma’s ever-evolving pipeline of novel protein therapeutics, such as bi-specific antibodies, multimeric proteins and Fc-fusion proteins, CHO cells are being pushed to their productivity limits in drug development and manufacturing. Biopharmaceutical companies working on these promising new therapies are increasingly struggling with development challenges such as weak protein expression, low-yield purification steps, and poorly optimized analytical techniques. Without addressing these challenges, many of these new medicines capable of treating serious, intractable diseases would never advance out of the pre-clinical phase. Selexis has made its mark with its SUREtechnology Platform™ that facilitates the rapid, stable, and cost-effective generation of cell lines producing virtually any recombinant protein. KBI has a proven track record of delivering therapeutic candidates into the clinic by leveraging its strengths in process development and analytics. Moreover, KBI and Selexis already have a long history of successful collaboration on behalf of their partners, as KBI has performed development and/or manufacturing services using more than 15 different Selexis generated cell lines since 2012.
“Combining KBI’s robust analytical, process development, and reliable high-quality manufacturing capabilities with our Selexis SUREtechnology Platform, puts us in a position to offer current and future partners the ability to take their R&D programs from transfection to investigational new drug (IND) application in less than nine months,” said Igor Fisch, PhD, Selexis Chief Executive Officer. “By delivering the fastest timelines in the industry, our partners will benefit from substantial cost savings and patients will have access to critical drugs sooner. We believe in the ability of our combined technologies and knowhow to contribute to the medicines of tomorrow that will save the lives of those facing diseases as diverse as HIV and various cancers.”
“The combination of Selexis and KBI results in a truly unique opportunity to create value for our clients,” said KBI President Tim Kelly, PhD. “KBI and Selexis share the same mission and values based on innovation, scientific excellence, true partnership with our clients, and focus on the patients we serve. Together, Selexis and KBI represent the next generation CDMO for the biopharmaceutical industry, which will translate into more high-quality biologics entering the clinic faster.”
Terms of the sales and purchase agreement are not disclosed.
About JSR Life Sciences Division
JSR Life Sciences Division is a business unit of JSR Corporation, which provides specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and Asia-Pacific. JSR Life Sciences is focused on diagnostics and research products and bioprocessing materials and services for the manufacture of biologics.
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell-line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, more than 76 biologic drug development programs and three commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.
About KBI Biopharma
KBI Biopharma, Inc. is a biopharmaceutical Contract Development and Manufacturing Organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage to academic/non-profit organizations, to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.
KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical protein characterization techniques toward the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapy products for our clients. KBI was founded in 1996 and operates 4 facilities: Durham and Research Triangle Park (NC), Boulder (CO), and The Woodlands (TX).
Inquiries for JSR Life Sciences and KBI Biopharma, Inc.
Missy Bindseil, +1 830-237-9527
Media Inquiries for Selexis
Sam Brown Inc.
Mike Beyer, +1 312-961-2502
Company Inquiries for Selexis
Robert Meister, +1 602-953-1716
Head, Corporate Communications
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom